CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC

ABSTRACT:

SUBMITTER: Lee J 

PROVIDER: S-EPMC12343357 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature